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Background: Vital signs sensing using wireless medical sensors
are promising alternatives to conventional, in-hospital healthcare
systems.
Methods and Results: In this work, a intelligent telemetry system
for ECG monitoring is proposed. This sensor system combined
with an appropriate wireless protocol for data communication
with capacitive ECG signal sensing and processing. This work
contains two units: ECG signal sensor unit and monitoring unit.
ECG signal sensor unit: The high coupling impedance of the
capacitive coupled electrode has necessitated the development of
specialized capacitive sensing techniques. In the sensor below,
the amplifier electronics are shielded and placed as close as
possible to the electrode to limit pickup of external signals. The
Heart beat sensor consisting of the dry wireless electrode is
designed to give digital output of heart beat when a finger is placed
on it. The PICMicrocontroller plays themajor role in analyzing the
measured ECG signal. The ECG signal is sensed with the help of
heart beat sensor. The measured signal is compared with the
reference signal with PIC 16F887 Microcontroller. The current
status of the patient along with the measured waveform is sent to
the monitoring system through the Global System for Mobile
communication technology. With this system the following six
different cardiac disorders can be detected. 1 Supraventricular
Tachycardia (SVT), 2 Tachycardia, 3 Bradycardia, 4 Atrial Fibril-
lation, 5 Myocardial Infarction and 6 Wolff Parkinson syndrome.
Conclusions: The equipment developed in this project meets its
requirements of providing a wearable wireless ECG monitoring in
the comfort of a patients house. In the measurement tests all the
information sent through GSM wireless communication arrived
correctly to the mobile receiver. The speed of the communication
was enough to receive all the information and the noise levels
were low.
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Background: Cyanotic CHD comprises up to 22.25% of cases of all
causes of CHD. There is lack of data about the present spectrum of
congenital cyanotic heart disease in the paediatric age group. The
present study was undertaken to determine the spectrum of pa-
tients with congenital cyanotic heart disease in the paediatric age
group in tertiary paediatric cardiac care clinic.
Methods: All children aged 0e18 years with suspected cyanotic
CHD were provisionally included in this retrospective observa-
tional study. They underwent a thorough echocardiographic
evaluation, and those patients who had definitive diagnosis of
congenital cyanotic heart disease were included for final analysis.
Results: A total of 223 children met the inclusion criteria. Tetral-
ogy of Fallot and its variant were the most common congenital
cyanotic heart disease with a proportion of about 47.04 %. Other
common malformations were d- transposition of great arteries
(9.4 %), Total anomalous pulmonary venous connection total
anomalous pulmonary venous connection (9.8 %), Double outlet
right ventricle (8.5 %), tricuspid atresia and Ebstein’s anomaly 
hypoplastic left-heart syndrome, truncus arteriosus, and complex
CHD such as single ventricle.
Conclusions: Tetralogy of Fallot and its variants were the most
common cyanotic heart disease diagnosed in our patients. As
there were a significant proportion of cases with complex cyanotic
CHD, cardiologists should be familiar with the diagnosis and
management of all these complex congenital malformations of
the heart.
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Background: Alerted substrate metabolism exists in heart failure
(HF). Optimizing myocardial energy metabolism with modulators
(eg. trimetazidine: TMZ) allows more efficacious energy produc-
tion from glucose than from free fatty acids. Although TMZ has
been studied in ischemic HF, more data are needed in dilated
cardiomyopathy (DCM).
Methods: 100 patients of DCM (mean age 47.7 yrs, NYHA class 2.17,
LVEF 27.3%) were randomized to TMZ (20 mg tid, n¼50) Vs con-
ventional therapy (n ¼ 50). Functional status, BNP & echocardio-
graphic parameters were assessed at 3-6 months.
Results: Baseline characteristics were comparable among the two
groups. At 3months, TMZ group had significantly improved NYHA
class (2.25 vs 1.85, p0.001), 6 min walk test (349.7 vs 402 m, p0.001),
LVD-36 score (25.5 vs 21, p0.001) & BNP (744.7 vs 248.3pg/ml,
p0.001). Significant improvement was also seen in LV end-systolic
(LVESV, 87.1 ± 27.5 vs 78.5 ± 24.9ml/m2, p0.001) & LV end-diastolic
volumes (LVEDV 117.6±29.3 vs 110.9±27.4 ml/m2, p0.001), LVEF (27
vs 30.9%, p0.001) and LV wall stress (90.2 ± 18.9 vs 71.1 ± 13.2dyn/
cm2, p0.0001). The % change in LVESV, LVEDV, LVEF & LV wall
stress was -10.3%, -6.2%, -10.1% & -21.8% respectively. Other echo
parameters also improved after 3 month of TMZ (E/A ratio1.9 + 1.1
vs 1.2+0.6, p0.001, E/A VTI 2.7±1.9 vs 1.6±0.7, p0.001, Myocardial
performance index, MPI 0.8±0.2 vs 0.7±0.1, p0.0001) and TDI pa-
rameters (E/e'septal 19.7±9.9 vs 12.5±5.8, p0.001 and E/e' lateral
(13.3±5.2 vs 9.4±3.7, p0.0001). Patients not on TMZ had no signifi-
cant change in NYHA Class, LVD-36 scores, LV volumes or LVEF at
3 months although BNP levels & LV wall stress reduced, but to a
lesser extent than TMZ. Patients on TMZ had further improve-
ment in NYHA Class, 6 min walk test, BNP levels & all echocar-
diographic parameters at 6 months.
Conclusion: Metabolic modulators like trimetazidine have a po-
tential role to play in altering LV remodelling and improving LV
function in DCM. In this study, benefit was noted by 3 months &
further improvement at 6 months.
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